mGluR2/3 influences in primate prefrontal cortex: potential for therapeutics
mGluR2/3 对灵长类前额皮质的影响:治疗潜力
基本信息
- 批准号:8630805
- 负责人:
- 金额:$ 49.95万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-06-20 至 2017-05-31
- 项目状态:已结题
- 来源:
- 关键词:Adverse effectsAgonistAreaBehavioralBehavioral inhibitionBrain regionCellsClinicalCognitionCognitiveCognitive deficitsCyclic AMPDataDendritic SpinesDevelopmentDiscriminationDiseaseDoseExcitatory SynapseFamilyGeneticGlutamatesHealthHumanImmunoelectron MicroscopyIndependent LivingIndustryInjection of therapeutic agentIontophoresisLabelLinkLocationMediatingMetabotropic Glutamate ReceptorsMethodsMonkeysMutationN-MethylaspartateNeurogliaNeuronsPatientsPatternPerformancePharmaceutical PreparationsPhysiologyPositioning AttributePotassium ChannelPrefrontal CortexPrimatesProductionResearchRodentRoleSaccadesSchizophreniaShort-Term MemorySignal TransductionSiteSynapsesTask PerformancesTemporal LobeTestingTherapeuticWorkarea striataassociation cortexcognitive enhancementcognitive functiondensitydrug developmenteffective therapyflexibilityimprovedinterestmemory recognitionmetabotropic glutamate receptor 2metabotropic glutamate receptor 3neuropsychiatrypostsynapticpresynapticpreventreceptorresearch studyresponserestorationsensory cortexsynaptic inhibitiontherapeutic targettransmission process
项目摘要
DESCRIPTION (provided by applicant): The proposed research will provide the first study of metabotropic glutamate receptor mGluR2/3 influences on dorsolateral prefrontal cortex (dlPFC) function in primates, a brain region greatly afflicted in patients with schizophrenia. Group II metabotropic glutamate receptors (mGluR2, mGluR3) are potential therapeutic targets, and genetic alterations of mGluR3 are increasingly associated with schizophrenia. However, there has been no research on how these receptors influence dlPFC circuits in primates, where there are likely evolutionary differences. The proposed research will determine the pre- vs. post-synaptic location of mGluR2 vs. mGluR3 in primate dlPFC circuits, and how mGluR2/3 stimulation influences dlPFC neuronal firing and cognitive function. As selective mGluR2 and mGluR3 agents are now available for research use, the proposed research will begin to dissect mGluR2 vs. mGluR3 effects on neuronal firing and cognitive performance. Preliminary data show that low doses of an mGluR2/3 agonist can enhance dlPFC neuronal firing and improve working memory performance in monkeys, with no evident side effects, suggesting clinical potential. Aim 1 will use multiple label, immunoelectron microscopy to localize mGluR2 and mGluR3 in pre- vs. post-synaptic sites in the primate dlPFC. Although rodent studies have focused on pre-synaptic localization, preliminary data from primate dlPFC indicate that mGluR2/3 are also localized post-synaptically next to layer III excitatory synapses, positioned to strengthen network firing. Localization in dlPFC will be compared to that in orbital PFC, temporal cortex and primary visual cortex, to see if the pattern in dlPFC is unique, or extends to other association and/or sensory cortices. Aim 2 will perform single unit recording of dlPFC neurons in monkeys performing a spatial working memory task to observe how alterations in mGluR2/3 signaling influence task-related network firing. These studies will be able to observe whether a drug treatment decreases neuronal firing (consistent with pre- synaptic inhibition of glutamate release), or increases neuronal firing (consistent with post-synaptic inhibition of cAMP-K+ channel actions). Results with mixed mGluR2/3 compounds will be compared to newly available, selective mGluR2 and mGluR3 agents to begin to define specific influences on dlPFC neuronal firing. Preliminary data indicate that low doses of an mGluR2/3 agonist greatly enhance the firing of dlPFC Delay cells that maintain working memory. Aim 3 will characterize the behavioral effects of the compounds used in Aim 2, in monkeys performing a battery of cognitive tasks. Initial data indicate that low doses of the mGlu2/3 agonist, (2R,4R)-APDC, markedly improve working memory performance with few side effects, highlighting the therapeutic potential of these mechanisms. The proposed experiments will compare the effects of mGluR2/3 compounds to those of selective mGluR2 and mGluR3 agents to see which receptor(s) underlie the cognitive enhancement. These data will provide essential information for guiding therapeutic strategies for cognitive enhancement in schizophrenia, and for understanding how insults to mGluR3 can impact cognitive function.
描述(由申请人提供):拟议的研究将首次研究代谢性谷氨酸受体mGluR2/3对灵长类动物背外侧前额叶皮质(dlPFC)功能的影响,这是精神分裂症患者的一个大脑区域。II组代谢性谷氨酸受体(mGluR2、mGluR3)是潜在的治疗靶点,mGluR3的遗传改变与精神分裂症的关系越来越密切。然而,目前还没有关于这些受体如何影响灵长类动物dlPFC回路的研究,灵长类动物可能存在进化差异。本研究将确定mGluR2和mGluR3在灵长类动物dlPFC回路中的突触前和突触后位置,以及mGluR2/3刺激如何影响dlPFC神经元放电和认知功能。随着选择性mGluR2和mGluR3药物现在可用于研究,拟议的研究将开始分析mGluR2和mGluR3对神经元放电和认知表现的影响。初步数据显示,低剂量mGluR2/3激动剂可增强dlPFC神经元放电,改善猴子的工作记忆表现,且无明显副作用,具有临床应用潜力。目的1将使用多重标记,免疫电镜定位mGluR2和mGluR3在灵长类动物dlPFC突触前和突触后的位置。虽然啮齿类动物的研究主要集中在突触前定位,但灵长类动物dlPFC的初步数据表明,mGluR2/3也定位在突触后,靠近第三层兴奋性突触,定位于加强网络放电。将dlPFC的定位与眼眶PFC、颞叶皮层和初级视觉皮层的定位进行比较,看看dlPFC的定位模式是独特的,还是延伸到其他联想和/或感觉皮层。目的2将对执行空间工作记忆任务的猴子的dlPFC神经元进行单单元记录,以观察mGluR2/3信号的改变如何影响任务相关网络的激活。这些研究将能够观察药物治疗是减少神经元放电(与谷氨酸释放的突触前抑制一致),还是增加神经元放电(与cAMP-K+通道作用的突触后抑制一致)。混合mGluR2/3化合物的结果将与新获得的选择性mGluR2和mGluR3药物进行比较,以开始确定对dlPFC神经元放电的具体影响。初步数据表明,低剂量的mGluR2/3激动剂可大大增强维持工作记忆的dlPFC延迟细胞的放电。目标3将描述目标2中使用的化合物对猴子执行一系列认知任务的行为影响。初步数据表明,低剂量的mGlu2/3激动剂(2R,4R)-APDC可显著改善工作记忆表现,且几乎没有副作用,突出了这些机制的治疗潜力。拟议的实验将比较mGluR2/3化合物与选择性mGluR2和mGluR3药物的作用,以了解哪些受体是认知增强的基础。这些数据将为指导精神分裂症认知增强的治疗策略以及理解mGluR3的损伤如何影响认知功能提供重要信息。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
AMY F.T. ARNSTEN其他文献
AMY F.T. ARNSTEN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('AMY F.T. ARNSTEN', 18)}}的其他基金
Prefrontal impairment with stress- NE receptor subtype mechanisms.
与压力-NE受体亚型机制有关的前额损伤。
- 批准号:
10655735 - 财政年份:2023
- 资助金额:
$ 49.95万 - 项目类别:
Development of GCPII inhibitors for the treatment of age-related cognitive disorders
开发用于治疗年龄相关认知障碍的 GCPII 抑制剂
- 批准号:
10410566 - 财政年份:2020
- 资助金额:
$ 49.95万 - 项目类别:
Development of GCPII inhibitors for the treatment of age-related cognitive disorders
开发用于治疗年龄相关认知障碍的 GCPII 抑制剂
- 批准号:
10261462 - 财政年份:2020
- 资助金额:
$ 49.95万 - 项目类别:
Development of GCPII inhibitors for the treatment of age-related cognitive disorders
开发用于治疗年龄相关认知障碍的 GCPII 抑制剂
- 批准号:
10633273 - 财政年份:2020
- 资助金额:
$ 49.95万 - 项目类别:
Development of GCPII inhibitors for the treatment of age-related cognitive disorders
开发用于治疗年龄相关认知障碍的 GCPII 抑制剂
- 批准号:
10028000 - 财政年份:2020
- 资助金额:
$ 49.95万 - 项目类别:
Preclinical assessment of GCPII inhibitors for cognition and tau pathology
GCPII 抑制剂对认知和 tau 病理学的临床前评估
- 批准号:
10541131 - 财政年份:2019
- 资助金额:
$ 49.95万 - 项目类别:
Preclinical assessment of GCPII inhibitors for cognition and tau pathology
GCPII 抑制剂对认知和 tau 病理学的临床前评估
- 批准号:
10321239 - 财政年份:2019
- 资助金额:
$ 49.95万 - 项目类别:
Preclinical assessment of GCPII inhibitors for cognition and tau pathology
GCPII 抑制剂对认知和 tau 病理学的临床前评估
- 批准号:
10625706 - 财政年份:2019
- 资助金额:
$ 49.95万 - 项目类别:
Rapid actions of ketamine in the prefrontal cortex
氯胺酮在前额皮质中的快速作用
- 批准号:
9901576 - 财政年份:2016
- 资助金额:
$ 49.95万 - 项目类别:
Highly evolved brain circuits in primates: molecular vulnerabilities for disease
灵长类动物高度进化的大脑回路:疾病的分子脆弱性
- 批准号:
8558580 - 财政年份:2013
- 资助金额:
$ 49.95万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 49.95万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 49.95万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 49.95万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 49.95万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 49.95万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 49.95万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 49.95万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 49.95万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 49.95万 - 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
- 批准号:
23K05057 - 财政年份:2023
- 资助金额:
$ 49.95万 - 项目类别:
Grant-in-Aid for Scientific Research (C)














{{item.name}}会员




